JP2025513929A5 - - Google Patents
Info
- Publication number
- JP2025513929A5 JP2025513929A5 JP2024563327A JP2024563327A JP2025513929A5 JP 2025513929 A5 JP2025513929 A5 JP 2025513929A5 JP 2024563327 A JP2024563327 A JP 2024563327A JP 2024563327 A JP2024563327 A JP 2024563327A JP 2025513929 A5 JP2025513929 A5 JP 2025513929A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- ras
- subject
- farnesyltransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305636 | 2022-04-28 | ||
| EP22305636.7 | 2022-04-28 | ||
| EP22306602.8 | 2022-10-21 | ||
| EP22306602 | 2022-10-21 | ||
| PCT/EP2023/061079 WO2023209073A1 (en) | 2022-04-28 | 2023-04-27 | Combination of ras inhibitors and farnesyltransferase inhibitors for the treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513929A JP2025513929A (ja) | 2025-04-30 |
| JP2025513929A5 true JP2025513929A5 (https=) | 2026-04-28 |
Family
ID=86378289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563327A Pending JP2025513929A (ja) | 2022-04-28 | 2023-04-27 | がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250262211A1 (https=) |
| EP (1) | EP4514356A1 (https=) |
| JP (1) | JP2025513929A (https=) |
| KR (1) | KR20250002557A (https=) |
| WO (1) | WO2023209073A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4719410A1 (en) * | 2023-05-31 | 2026-04-08 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for treatment of kras-dependent cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335077A1 (en) * | 2013-05-07 | 2014-11-13 | Leonard Girnita | Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors |
| US11331312B2 (en) * | 2014-04-25 | 2022-05-17 | Memorial Sloan-Kettering Cancer Center | Treatment of H-Ras-driven tumors |
| US20230285498A1 (en) * | 2020-08-07 | 2023-09-14 | City Of Hope | Treatments for cancers having kras mutations |
-
2023
- 2023-04-27 KR KR1020247038308A patent/KR20250002557A/ko active Pending
- 2023-04-27 JP JP2024563327A patent/JP2025513929A/ja active Pending
- 2023-04-27 EP EP23723466.1A patent/EP4514356A1/en active Pending
- 2023-04-27 WO PCT/EP2023/061079 patent/WO2023209073A1/en not_active Ceased
- 2023-04-27 US US18/856,328 patent/US20250262211A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grimes et al. | Conjunctival melanoma: current treatments and future options | |
| Blecua et al. | The DNA methylation landscape of hematological malignancies: an update | |
| Jain et al. | Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities | |
| Oettle et al. | Adjuvant therapy in pancreatic cancer: a critical appraisal | |
| Jin et al. | Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2020523354A5 (https=) | ||
| Souglakos et al. | Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer | |
| JP2019506392A5 (https=) | ||
| JPWO2022269525A5 (https=) | ||
| JP2025513929A5 (https=) | ||
| Dabney et al. | Molecular pathways and targeted therapy in cholangiocarcinoma | |
| Malakar et al. | The role of BRAF inhibitors in the management of ameloblastoma: a literature review | |
| Li et al. | Unraveling the role of TP53 in colorectal cancer therapy: from wild-type regulation to mutant | |
| Jin et al. | Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment | |
| Kawai et al. | Phase I/II study of preoperative chemoradiotherapy with TEGAFIRI for locally advanced rectal cancer | |
| JP2025026846A5 (https=) | ||
| Ning et al. | Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study | |
| Zhou et al. | Advances in immunotherapy and targeted therapy for pancreatic cancer | |
| JPWO2022182857A5 (https=) | ||
| Yu et al. | Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer | |
| Lee | Disease modifying agents of myeloproliferative neoplasms: a review | |
| Chan et al. | CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis | |
| White et al. | Infigratinib for the treatment of metastatic or locally advanced cholangiocarcinoma with known FGFR2 gene fusions or rearrangements | |
| Yoon et al. | Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells |